Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Market launch would follow 13 months after approval, placing realistic patient access between late 2027 and mid-2028
4 The mechanisms are independent one primes the pituitary to synthesise and release GH, the other amplifies that release and suppresses somatostatin, the bodys natural brake on GH
These findings underscore the multifunctionality of GLP-1R as a therapeutic target and its involvement in various biological processes, emphasizing its role in addressing complex disease mechanisms
Therapeutic modulation of GPX4 and iron homeostasis may offer novel strategies for OA management where cartilage iron imbalance is implicated
